KLK5 and atopic eczema: In Spink5−/−Klk5−/−, Klk5 was genetically ablated on the Netherton background to provide proof of concept for drugging the KLK5 activity for pharmacotherapy of Netherton syndrome and, potentially, other diseases like atopic dermatitis.